Cargando…

Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer

INTRODUCTION: Resistance to second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), afatinib, is the most significant challenge in the clinical management of non-small cell lung cancer (NSCLC), and the underlying mechanisms remain unclear. METHODS: Genomic signatures...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Xiaoxi, Zhou, Renyu, Lu, Yuanzhi, Zhang, Ying, Chen, Qiang, Li, Yin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595596/ https://www.ncbi.nlm.nih.gov/pubmed/34804966 http://dx.doi.org/10.3389/fonc.2021.763035

Ejemplares similares

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
por: Kang, Liping, et al.
Publicado: (2023)

Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study
por: Song, Zhengbo, et al.
Publicado: (2021)

BIRC3 and BIRC5: multi‐faceted inhibitors in cancer
por: Frazzi, Raffaele
Publicado: (2021)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
por: Morin-Ben Abdallah, Sami, et al.
Publicado: (2017)

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
por: Yang, James Chih-Hsin, et al.
Publicado: (2022)

Genetic Variants of CLEC4E and BIRC3 in Damage-Associated Molecular Patterns-Related Pathway Genes Predict Non-Small Cell Lung Cancer Survival
por: Liu, Lihua, et al.
Publicado: (2021)

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
por: Yuan, Bo, et al.
Publicado: (2020)

Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature
por: Jobe, Amanda L, et al.
Publicado: (2018)

Afatinib in Non–Small Cell Lung Cancer
por: Wirth, Scott M.
Publicado: (2015)

Bioinformatics analysis of BIRC5 in human cancers
por: Ye, Han-Bin, et al.
Publicado: (2022)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
por: Ma, Chunhua, et al.
Publicado: (2019)

Study of circulating IgG antibodies to BIRC5 and MYC in non-small cell lung cancer
por: Ye, Leiguang, et al.
Publicado: (2015)

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
por: Manca, Paolo, et al.
Publicado: (2017)

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
por: Zhao, Lingling, et al.
Publicado: (2021)

Corrigendum: Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
por: Ma, Chunhua, et al.
Publicado: (2019)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Afatinib-Associated Cutaneous Toxicity: A Correlation of Severe Skin Reaction with Dramatic Tumor Response in a Woman with Exon 19 Deletion Positive Non-Small-Cell Lung Cancer
por: Osborn, Lindsay P, et al.
Publicado: (2016)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
por: Passaro, Antonio, et al.
Publicado: (2021)

Toxic epidermal necrosis associated with afatinib: A case report and literature review
por: Yang, Wei, et al.
Publicado: (2023)

Afatinib for the treatment of metastatic non-small cell lung cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report
por: Nishimura, Jun, et al.
Publicado: (2017)

Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance
por: Kong, Fanming, et al.
Publicado: (2021)

Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature
por: Eze, Chukwuka, et al.
Publicado: (2017)

Identification of prognostic significance of BIRC5 in breast cancer using integrative bioinformatics analysis
por: Dai, Jian-bo, et al.
Publicado: (2020)

Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2014)

Identification and Validation Prognostic Impact of MiRNA-30a-5p in Lung Adenocarcinoma
por: Jiang, Xiulin, et al.
Publicado: (2022)

BIRC5 Modulates PD-L1 Expression and Immune Infiltration in Lung Adenocarcinoma
por: Ma, Teng, et al.
Publicado: (2022)

Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
por: Sosa Iglesias, Venus, et al.
Publicado: (2018)

The emerging role of circular RNAs in drug resistance of non-small cell lung cancer
por: Yan, Tinghao, et al.
Publicado: (2022)

Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib
por: Griebsch, Ingolf, et al.
Publicado: (2014)

Increased Expression of BIRC2, BIRC3, and BIRC5 from the IAP Family in Mesenchymal Stem Cells of the Umbilical Cord Wharton's Jelly (WJSC) in Younger Women Giving Birth Naturally
por: Gil-Kulik, Paulina, et al.
Publicado: (2020)

Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
por: Zhang, Hongye, et al.
Publicado: (2020)

Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
por: Longton, Eleonore, et al.
Publicado: (2018)

Corrigendum: Identification and Validation Prognostic Impact of miRNA-30a-5p in Lung Adenocarcinoma
por: Jiang, Xiulin, et al.
Publicado: (2022)

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients
por: Wang, Lei-Yun, et al.
Publicado: (2018)

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2022)

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
por: Kim, Ye-Jin, et al.
Publicado: (2023)

Transformation to small cell lung cancer after first-line afatinib treatment
por: Shiroyama, Takayuki, et al.
Publicado: (2018)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_60k4oscdveb8pmdd95dov17o5u